Navigation Links
Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC
Date:9/18/2007

pproximately 63 percent of the total number of staphylococci infections. Over the last five years, MRSA infections have increased nearly ten-fold and currently represent more than 50 percent of emergency department cSSSIs. Data from a 2003 CDC study suggests that about 12 percent of clinical MRSA infections are community-associated.

About Telavancin Collaboration

In November 2005, Theravance entered into a collaboration arrangement with Astellas Pharma Inc. (Astellas) for the development and commercialization of telavancin worldwide except Japan. In July 2006, Theravance and Astellas expanded the collaboration to include Japan. Under the terms of the collaboration, Theravance will lead the development of telavancin for the treatment of cSSSI and hospital-acquired pneumonia, and will collaborate substantially with Astellas in marketing in the United States for the first three years. Astellas will lead all other development, regulatory, manufacturing, sales and marketing activities.

About Theravance

Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections and gastrointestinal motility dysfunction. Of the five programs in development, four are in late stage -- its telavancin program focusing on treating serious Gram-positive bacterial infections with Astellas Pharma Inc., the Gastrointestinal Motility Dysfunction program, the Beyond Advair collaboration with GlaxoSmithKline plc and TD-1792 for the treatment of serious Gram-positive infections. By leveraging its proprietary insight of multivalency toward drug discovery focused on validated targets, Theravance is pursuing a next generation strategy designed to discover superior medicines in large markets. For more information, please visit the company's web site at
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Assess the In Vivo Activation of Signal Transduction Pathways with PathDetect Reporting Systems
2. New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter
3. Signal Transduction Reporting Systems Using Cis-Acting Enhancer Elements
4. Stable HeLa Luciferase Reporter Cell Lines Expressing GAL4 Fusion Transactivators
5. Versatile Reporter Vectors for Monitoring Viral Transduction
6. In Vivo Signal Transduction Pathway Reporting Systems
7. Improved Vectors for PathDetect Trans-Reporting Systems
8. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
9. Cis-Reporting System Monitors Intracellular Calcium Mobilization
10. Cis-Reporting System Monitors Intracellular Calcium Mobilization
11. PatchMan - Test Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... The report "1,6-Hexanediol Market by Application and ... analyzes the global market on the basis of ... details such as the key drivers, current trends ... Browse 81 Market Data Tables and 29 Figures ... “1,6-Hexanediol Market by Application and by Geography - ...
(Date:10/18/2014)... (PRWEB) October 18, 2014 The Asia-Pacific ... concerned market in Asia-Pacific with analysis and forecast of ... and is expected to reach $51,362.6 million by 2018, ... , Browse through the TOC of the Asia-Pacific hardware ... in-depth analysis provided. This also provides a glimpse of ...
(Date:10/18/2014)... 18, 2014 The Asian Electronic Medical Record ... Asian with analysis and forecast of revenue. The electronic medical ... to $2,328.0 million by 2018, at a CAGR of 9.4% ... the Asian Electronic Medical Record (EMR) market, to get an ... glimpse of the segmentation of the market in the same ...
(Date:10/18/2014)... to a new market research report “Hydraulic Fracturing Market ... Forecasts up till 2017”, hydraulic fracturing market will grow ... expected to increase from $40 billion in 2012 to ... same period. North America is expected to lead the ... horse power supplied by the year 2011. , Make ...
Breaking Biology Technology:1,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 21,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 31,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 41,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 5The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 3The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 2The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 3The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 4The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 5Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 2Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 3Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 4
... (Nasdaq: AMLN ) issued the following statement ... Eastbourne Capital Management, L.L.C., made public earlier today:"After significant ... unable to achieve a settlement with Eastbourne and Carl ... shareholders. Of course, we continue to remain open to ...
... ATLANTA, May 20 Germany will present itself ... locations at this year,s BIO,International Convention. Under the ... will provide invaluable insight into the,latest research results ... The,German research landscape and the regulatory framework conditions ...
... N.C., May 20 Asymchem Laboratories, Inc., a leading ... Products to the pharmaceutical industry, with sites in ... the recent addition of Dr. Chris Huber as ... the table over 15 years experience in the ...
Cached Biology Technology:Amylin Responds to Eastbourne Letter 2Amylin Responds to Eastbourne Letter 3Amylin Responds to Eastbourne Letter 4BIO International Convention 2009: Research Location Germany Presents Potential in Regenerative Medicine 2Dr. Chris Huber Joins Asymchem Laboratories Inc. as Director of Chemical Development 2
(Date:10/17/2014)... To date, antidotes ... doctors are often limited to supportive therapy such as induced ... of drugs involved. So what can be done if a ... professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences at ... "The task was to develop an agent that could eliminate ...
(Date:10/16/2014)... efficiently, they are anything but sustainable: environmental damage ... is becoming increasingly evident. Despite their disadvantages, however, ... regarded as the sole possibility of achieving higher ... Bernhard Schmid, an ecology professor at the University ... agriculture and forestry. After all, a new study ...
(Date:10/15/2014)... risk from strains of influenza virus increases with the ... become complacent that the most substantial threats have been ... pandemics arise when a new virus strain – against ... spreads in the human population. There have been five ... of which – the 1918 Spanish Flu – cost ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
... photovoltaic (PV) cells world-wide produced a peak amount of electricity ... located in Europe. Similarly to previous years, this shows the ... new solar systems were installed. By the end of 2009, ... installed) was 16 GW, which is about 70% of the ...
... A surface molecule on bacteria that instructs bone cells ... bone disease, says a scientist speaking at the Society for ... from bacteria could be a way of treating painful bone ... by Meticillin-resistant Staphylococcus aureus (MRSA). Bone disease, ...
... 1. A Low-carb Diet Based on Animal Protein May ... low-carbohydrate diet produces weight loss and improves some cardiovascular ... may depend on the type of protein and fat ... a low-carbohydrate diet for 26 and 20 years respectively. ...
Cached Biology News:Three-quarters of new solar systems worldwide were installed in the EU in 2009 2Three-quarters of new solar systems worldwide were installed in the EU in 2009 3Interrupting death messages to treat bone disease 2Embargoed news from Annals of Internal Medicine 2
... transient, cytoplasmic expression of an N-terminal FLAG® ... or selection marker from bicistronic mRNA. ... and MCS2 for transcription of a single ... is useful for protein-protein interaction studies, multi-subunit ...
...
Mouse monoclonal antibody raised against a partial recombinant SCARB2. NCBI Entrez Gene ID = SCARB2...
Alpha-2-antiplasmin precursor (Alpha-2-plasmin inhibitor) (Alpha-2-PI) (Alpha-2-AP). [Source:Uniprot/SWISSPROT;Acc:P08697] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: